ECSP18038014A - Bloqueador del canal de sodio - Google Patents

Bloqueador del canal de sodio

Info

Publication number
ECSP18038014A
ECSP18038014A ECIEPI201838014A ECPI201838014A ECSP18038014A EC SP18038014 A ECSP18038014 A EC SP18038014A EC IEPI201838014 A ECIEPI201838014 A EC IEPI201838014A EC PI201838014 A ECPI201838014 A EC PI201838014A EC SP18038014 A ECSP18038014 A EC SP18038014A
Authority
EC
Ecuador
Prior art keywords
sodium channel
channel blocker
present
prevention
pharmaceutically acceptable
Prior art date
Application number
ECIEPI201838014A
Other languages
English (en)
Inventor
Chun Ho Lee
Il-Hwan Kim
Sung-Young Kim
Hyo Shin Kim
Myunggi Jung
Hyung-Geun Lee
Sun Ah Jun
Ji Sung Yoon
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of ECSP18038014A publication Critical patent/ECSP18038014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un compuesto representado por la Fórmula Química, o una sal farmacéuticamente aceptable del mismo. El compuesto según la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades relacionadas con bloqueantes de canales de sodio.
ECIEPI201838014A 2015-11-13 2018-05-18 Bloqueador del canal de sodio ECSP18038014A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150159637 2015-11-13

Publications (1)

Publication Number Publication Date
ECSP18038014A true ECSP18038014A (es) 2018-05-31

Family

ID=58695815

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201838014A ECSP18038014A (es) 2015-11-13 2018-05-18 Bloqueador del canal de sodio

Country Status (29)

Country Link
US (1) US10227338B2 (es)
EP (1) EP3375782B1 (es)
JP (1) JP6559894B2 (es)
KR (1) KR102245930B1 (es)
CN (1) CN108349963B (es)
AU (1) AU2016351526B2 (es)
BR (1) BR112018009754B1 (es)
CA (1) CA3003119C (es)
CL (1) CL2018001281A1 (es)
CO (1) CO2018005064A2 (es)
EC (1) ECSP18038014A (es)
ES (1) ES2821962T3 (es)
HR (1) HRP20201695T1 (es)
HU (1) HUE052569T2 (es)
MA (1) MA43231B1 (es)
MX (1) MX376469B (es)
MY (1) MY194015A (es)
NZ (1) NZ742069A (es)
PE (1) PE20181301A1 (es)
PH (1) PH12018500999A1 (es)
PL (1) PL3375782T3 (es)
PT (1) PT3375782T (es)
RS (1) RS60927B1 (es)
RU (1) RU2705578C1 (es)
SA (1) SA518391540B1 (es)
SG (1) SG11201803867TA (es)
SI (1) SI3375782T1 (es)
TN (1) TN2018000157A1 (es)
WO (1) WO2017082688A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201903348UA (en) * 2016-10-17 2019-05-30 Genentech Inc Therapeutic compounds and methods of use thereof
TW202003490A (zh) * 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
WO2020052509A1 (zh) * 2018-09-10 2020-03-19 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
CN112759559B (zh) * 2019-11-06 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
HU230056B1 (hu) * 2001-03-12 2015-06-29 Ono Pharmaceutical Co., Ltd N-fenil-arilszulfonamidok, intermediereik, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
JP2006290791A (ja) 2005-04-11 2006-10-26 Astellas Pharma Inc アゾール置換スルホニルベンゼン誘導体
EP1901747A2 (en) * 2005-05-25 2008-03-26 Ingenium Pharmaceuticals AG Pyrimidine-based cdk inhibitors for treating pain
US7888345B2 (en) 2006-06-09 2011-02-15 Merck Sharp & Dohme Corp. Benzaepinones as sodium channel blockers
EP2139852A1 (en) * 2006-12-19 2010-01-06 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
JP2008290791A (ja) * 2007-05-22 2008-12-04 Funai Electric Co Ltd 画像形成装置
WO2009012242A2 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
EA020460B1 (ru) * 2009-01-12 2014-11-28 Пфайзер Лимитед Производные сульфонамида
ES2525581T3 (es) 2010-07-12 2014-12-26 Pfizer Limited Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
EP2773641B1 (en) 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
WO2013086229A1 (en) 2011-12-07 2013-06-13 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
WO2013088315A1 (en) 2011-12-15 2013-06-20 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
EP2906558B1 (en) * 2012-10-15 2020-09-02 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers, preparation method thereof and use thereof
WO2015130957A1 (en) * 2014-02-27 2015-09-03 Zalicus Pharmaceuticals, Ltd. Heterocyclic inhibitors of the sodium channel

Also Published As

Publication number Publication date
US10227338B2 (en) 2019-03-12
PT3375782T (pt) 2020-08-05
CO2018005064A2 (es) 2018-06-20
SA518391540B1 (ar) 2021-04-06
AU2016351526B2 (en) 2019-02-21
ES2821962T3 (es) 2021-04-28
EP3375782A1 (en) 2018-09-19
CN108349963B (zh) 2021-03-30
MA43231B1 (fr) 2020-08-31
CL2018001281A1 (es) 2018-08-31
RS60927B1 (sr) 2020-11-30
EP3375782A4 (en) 2019-05-15
PH12018500999A1 (en) 2019-01-28
HUE052569T2 (hu) 2021-05-28
PE20181301A1 (es) 2018-08-09
WO2017082688A1 (ko) 2017-05-18
HRP20201695T1 (hr) 2020-12-25
BR112018009754B1 (pt) 2024-01-23
AU2016351526A1 (en) 2018-05-17
NZ742069A (en) 2019-08-30
BR112018009754A8 (pt) 2019-02-26
CN108349963A (zh) 2018-07-31
MY194015A (en) 2022-11-08
PL3375782T3 (pl) 2021-02-22
KR102245930B1 (ko) 2021-04-29
HK1251229A1 (zh) 2019-01-25
BR112018009754A2 (pt) 2018-11-06
MX2018005940A (es) 2018-08-14
JP6559894B2 (ja) 2019-08-14
JP2018533606A (ja) 2018-11-15
KR20170056461A (ko) 2017-05-23
SI3375782T1 (sl) 2020-10-30
SG11201803867TA (en) 2018-06-28
US20180346459A1 (en) 2018-12-06
TN2018000157A1 (en) 2019-10-04
CA3003119A1 (en) 2017-05-18
MX376469B (es) 2025-03-07
RU2705578C1 (ru) 2019-11-08
CA3003119C (en) 2019-10-22
EP3375782B1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
CO2020014586A2 (es) Compuestos
DOP2020000112A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
CO2019004034A2 (es) Compuesto de piridina
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
MX2016011160A (es) Tratamiento de afecciones asociadas con la hiperinsulinemia.
CL2018002583A1 (es) Derivado de morfolina
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
AR095097A1 (es) Compuestos de fenoxietoxi
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
ECSP18038014A (es) Bloqueador del canal de sodio
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
DOP2018000042A (es) Antagonistas del receptor de cgrp
MX394782B (es) Compuestos para el tratamiento de enfermedades asociadas con una disfunción mitocondrial.
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
AR110770A1 (es) Moduladores del canal de potasio
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
MX2022006984A (es) Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina.
MX2022000651A (es) Proceso mejorado para preparar ozanimod.
AR115865A2 (es) Compuestos terapéuticos
MX2018007796A (es) Compuestos de fenilimidazol.
UY36096A (es) Inhibir el canal de iones del potencial del receptor transitorio a1